Zelboraf Den Europæiske Union - dansk - EMA (European Medicines Agency)

zelboraf

roche registration gmbh - vemurafenib - melanom - antineoplastiske midler - vemurafenib er indiceret som monoterapi til behandling af voksne patienter med braf-v600-mutations-positiv uopløselig eller metastatisk melanom.

Cisplatin "Ebewe" 1 mg/ml koncentrat til infusionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

cisplatin "ebewe" 1 mg/ml koncentrat til infusionsvæske, opløsning

ebewe pharma ges.m.b.h. nfg. kg - cisplatin - koncentrat til infusionsvæske, opløsning - 1 mg/ml

Versatis 700 mg medicinsk plaster Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

versatis 700 mg medicinsk plaster

grünenthal gmbh - lidocain - medicinsk plaster - 700 mg

Versatis 700 mg medicinsk plaster Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

versatis 700 mg medicinsk plaster

paranova danmark a/s - lidocain - medicinsk plaster - 700 mg

Versatis 700 mg medicinsk plaster Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

versatis 700 mg medicinsk plaster

2care4 aps - lidocain - medicinsk plaster - 700 mg

Versatis 700 mg medicinsk plaster Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

versatis 700 mg medicinsk plaster

orifarm a/s - lidocain - medicinsk plaster - 700 mg

Iluvien 190 mikrogram intravitreal implantat i applikator Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

iluvien 190 mikrogram intravitreal implantat i applikator

alimera sciences europe ltd. - fluocinolonacetonid - intravitreal implantat i applikator - 190 mikrogram

Beovu Den Europæiske Union - dansk - EMA (European Medicines Agency)

beovu

novartis europharm limited  - brolucizumab - wet macular degeneration - oftalmologiske - beovu er indiceret hos voksne til behandling af neovaskulær (våd) aldersrelateret macula degeneration (amd).

Zeposia Den Europæiske Union - dansk - EMA (European Medicines Agency)

zeposia

bristol-myers squibb pharma eeig - ozanimod hydrochlorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunosuppressiva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Mekinist Den Europæiske Union - dansk - EMA (European Medicines Agency)

mekinist

novartis europharm limited - trametinib - melanom - antineoplastiske midler - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. ikke-småcellet lungekræft (nsclc)trametinib i kombination med dabrafenib er indiceret til behandling af voksne patienter med avanceret ikke-småcellet lungekræft med en braf v600 mutation.